Nevertheless, it is important to underline the importance to expand the genetic evaluation for RET germline variants in MTC or MEN2A patients also to exon 2, especially if genetic testing has excluded the presence of the more common variants located within other exons. The gene discussed is RET; the disease is medullary thyroid gland carcinoma.